Imeka
Imeka is currently the only company to combine diffusion imaging and AI to map white matter integrity and get insights on neuroinflammation, demyelination and axonal loss. Therefore, with our non-invasive technology, we minimize risks for our pharma and biotech clients in the development of treatments for neurodegenerative diseases. Imeka’s main goal is to play an influential role in the search and development of cures for brain disease. Imeka’s diffusion imaging tools are able to measure extracellular water fraction (free-water), which is sensitive neuroinflammation. The technology pioneered by Imeka enhances white matter imaging and has applications in important brain disease areas such as Multiple Sclerosis, Alzheimer and Parkinson.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Medical Research
- Market Focus:
- Internationally (various countries)
About Us
Imeka: Taking You Into the Future of White Matter Research
Our imaging abilities are powerful, unique, and non-invasive.
Imeka: Because data means nothing without analysis
Advanced white matter imaging—such as diffusion MRI (dMRI)—is a readily available technology that can pick up microstructural properties of the central nervous system. Data can be collected in as little as five minutes on a standard MRI machine.
It’s what you do with that data that makes all the difference.
Imeka’s ANIE (Advanced Neuro Imaging Endpoints) biomarker platform combines white matter imaging with artificial intelligence to analyze white matter MRI signals in greater detail than anyone else.